Cannabix Technologies (OTCPK:BLOZF) has announced a strategic partnership and development agreement with Omega Laboratories, which has been a global leader in providing abuse testing of forensic drugs for over two decades. This partnership marks a significant step forward for Cannabix as it looks to advance its innovative marijuana breathalyzer technology in the market.
Under the agreement, Omega will exclusively test Cannabix’s delta9 THC breath sample cartridges for drugs within North America for the next five years. In exchange for reaching specific milestones, Omega will receive 1 million shares of Cannabix (OTCPK:BLOZF) and 11 million special warrants. The partnership includes an ‘R&D Phase’ and a ‘Commercial Phase,’ during which the two parties will collaborate on determining pricing, licensing, and other revenue parameters.
This new agreement will pave the way for the commercialization of Cannabix’s marijuana breathalyzer technology. By teaming up with Omega Laboratories, Cannabix aims to expand its reach and bring its cutting-edge products to a wider audience. This partnership is expected to help Cannabix Technologies gain more credibility in the market and increase its chances of success.
